Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-84194-w
Abstract: CYP3A5 is the primary CYP3A subfamily enzyme expressed in the human kidney and its aberrant expression may contribute to a broad spectrum of renal disorders. Pharmacogenetic studies have reported inconsistent linkages between CYP3A5 expression and… read more here.
Keywords: renal disease; expression; cyp3a5 renal; cyp3a5 expression ... See more keywords
Inhibition of CYP3A4 and CYP3A5 expression by scutellarin is not mediated via the regulation of hsa-miR-27a, 27b, 148a, 298 and 451a levels
Sign Up to like & getrecommendations! Published in 2018 at "Xenobiotica"
DOI: 10.1080/00498254.2018.1555344
Abstract: Abstract 1. Scutellarin is a flavonoid glycoside widely used in the treatment of cardio-cerebrovascular diseases in China. In this study, we investigated the effect of scutellarin on cytochrome P450 3A4 (CYP3A4) and CYP3A5 expression. Furthermore,… read more here.
Keywords: hsa mir; cyp3a4 cyp3a5; hsa; cyp3a5 expression ... See more keywords
Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Transplantation"
DOI: 10.12659/aot.936276
Abstract: Background After renal transplantation, immunosuppressants should be administered to prevent organ rejection and prolong graft survival. One of them is tacrolimus, which is metabolized by the CYP3A enzyme family. The variability of the CYP3A5 gene… read more here.
Keywords: cyp3a5 expression; transplantation; transplantation outcomes; transplant recipients ... See more keywords